NIH Treatment Guidelines for Therapeutics
Paxlovid (ritonavir-boosted nirmatrelvir) is the preferred treatment recommended by the NIH Treatment Guidelines for high-risk patients with symptomatic COVID-19 infection.
Additional clinical considerations for Paxlovid can be found at the NIH Treatment Guidelines section on Paxlovid and prescribing tools and resources can be found at the DSHS webpage.
Other options in the NIH treatment guidelines include Veklury (remdesivir), bebtelovimab, and Lagevrio (molnupiravir). Veklury can be purchased from the distributor for outpatient use. Use the Guide For Healthcare Professionals for directions on ordering remdesivir for outpatient use.
Please see the side-by-side overview for a comparison of available therapeutics. Providers should reserve bebtelovimab for their patients who are unable to receive or access one of the preferred treatments.
Per the NIH Guidelines for Therapeutic Management of Non-hospitalized Adults update on April 8, 2022, the preferred therapies are listed in order of preference:
- Paxlovid
- Veklury (remdesivir)
Alternative therapies for use only when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:
- Bebtelovimab
- Lagevrio (molnupiravir)
Be Aware of New Paxlovid NDC
Providers may see an additional national drug code (NDC) for the packages of Paxlovid containing 300 mg nirmatrelvir and 100 mg ritonavir.
Pfizer has expanded manufacturing capability and has added an additional supplier of ritonavir. The new NDC will not affect either reporting or ordering in HPOP; however, the specific NDC will be needed for transfers and wastage. See page 29 of the Paxlovid Fact Sheet for additional information.
HPOP TIP: Inventory Filtered by Therapeutic Category
The products listed by default in your inventory section will be limited to the therapeutic category for your site.
For example, Evusheld will not be displayed if your site is not enrolled for the category ‘Monoclonal Antibody Special’.
 Note: You do not need to record zeros for products that are not in your inventory.
Resources Available for Therapeutic Providers
Access the links below to review any new and updated resources shared by the CDC, FDA, IDSA, and Pfizer.
HPOP Tip: Warning for Missing Therapeutic Inventory
A warning will be displayed when selecting a product as part of placing an order when a Provider has not reported inventory for a product since it was last ordered in HPOP.
 DSHS will not allocate to facilities that do not report inventory and administration regularly.
For more information, please review the HPOP Provider Portal User Guide page 5-9 for reporting.
CDC Webinar: 'What Clinicians Need to Know About Available Therapeutic Options for COVID-19'
On Thursday, June 16th, 2022, CDC hosted the webinar, ‘What Clinicians Need to Know About Available Therapeutic Options for COVID-19’ which discussed therapeutic options, including indications, efficacy, and distribution.
- Medications that are available that can reduce chances of severe illness and death from COVID-19 infection.
- Oral antivirals that are available that can reduce chances of severe illness and death from COVID-19 infection.
- The Food & Drug Administration emergency use authorizations (EUA) for certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get sick.
- The National Institutes of Health COVID-19 treatment guidelines for healthcare providers for treating COVID-19 at home or in an outpatient setting.
View the archive of the call at: https://emergency.cdc.gov/coca/calls/2022/callinfo_061622.asp.
|
